Comparative Pharmacology
Head-to-head clinical analysis: MULTAQ versus NEXTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MULTAQ versus NEXTERONE.
MULTAQ vs NEXTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a multichannel blocker that inhibits potassium currents (IKr, IKs, IK-ACh), sodium current (INa), and L-type calcium current (ICaL), and has antiadrenergic properties via noncompetitive blockade of beta-adrenergic receptors.
Class III antiarrhythmic agent; prolongs cardiac action potential duration by blocking potassium channels (IKr), primarily affecting the atria and ventricles.
400 mg orally twice daily with morning and evening meals.
Intravenous loading: 150 mg over 10 minutes, then 1 mg/min for 6 hours, followed by maintenance infusion of 0.5 mg/min. Oral: 400 mg twice daily for loading (total 1200 mg/day) for 7-10 days, then maintenance 200-400 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, allowing for twice-daily dosing.
Terminal elimination half-life of 58 days (range 25-110 days) due to extensive tissue distribution and slow release from lipid stores. Steady-state concentrations require approximately 3-6 months of chronic dosing.
Primarily fecal (84%) after biliary excretion; renal excretion accounts for <6% as unchanged drug and metabolites.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary excretion of metabolites is significant, with approximately 30-40% eliminated in feces. Renal excretion accounts for ~15-20% of total clearance as metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic